BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35806227)

  • 1. Non-Classical HLA Determinants of the Clinical Response after Autologous Stem Cell Transplantation for Systemic Sclerosis.
    Boukouaci W; Lansiaux P; Lambert NC; Picard C; Clave E; Cras A; Marjanovic Z; Farge D; Tamouza R
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients-High Efficacy of Rituximab.
    Gernert M; Tony HP; Fröhlich M; Schwaneck EC; Schmalzing M
    Front Immunol; 2021; 12():817893. PubMed ID: 35111167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy.
    Keret S; Henig I; Zuckerman T; Kaly L; Shouval A; Awisat A; Rosner I; Rozenbaum M; Boulman N; Dortort Lazar A; Molad Y; Sabbah F; Naffaa ME; Hardak E; Slobodin G; Rimar D
    Rheumatology (Oxford); 2024 May; 63(6):1534-1538. PubMed ID: 37672021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous hematopoietic stem cell transplantation promotes connective tissue remodeling in systemic sclerosis patients.
    Zanin-Silva DC; Santana-Gonçalves M; Kawashima-Vasconcelos MY; Lima-Júnior JR; Dias JBE; Moraes DA; Covas DT; Malmegrim KCR; Ramalho L; Oliveira MC
    Arthritis Res Ther; 2022 Apr; 24(1):95. PubMed ID: 35488348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis.
    Del Papa N; Pignataro F; Zaccara E; Maglione W; Minniti A
    Front Immunol; 2018; 9():2390. PubMed ID: 30386340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients.
    Farge D; Arruda LC; Brigant F; Clave E; Douay C; Marjanovic Z; Deligny C; Maki G; Gluckman E; Toubert A; Moins-Teisserenc H
    J Hematol Oncol; 2017 Jan; 10(1):21. PubMed ID: 28103947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis.
    Shouval R; Furie N; Raanani P; Nagler A; Gafter-Gvili A
    Biol Blood Marrow Transplant; 2018 May; 24(5):937-944. PubMed ID: 29374527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients.
    Lima-Júnior JR; Arruda LCM; Gonçalves MS; Dias JBE; Moraes DA; Covas DT; Simões BP; Oliveira MC; Malmegrim KCR
    Rheumatology (Oxford); 2021 Dec; 60(12):5538-5548. PubMed ID: 33724344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis.
    Arruda LCM; Lima-Júnior JR; Clave E; Moraes DA; Douay C; Fournier I; Moins-Teisserenc H; Covas DT; Simões BP; Farge D; Toubert A; Malmegrim KCR; Oliveira MC
    Bone Marrow Transplant; 2018 Oct; 53(10):1319-1327. PubMed ID: 29670207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern.
    Gernert M; Tony HP; Schwaneck EC; Gadeholt O; Schmalzing M
    Arthritis Res Ther; 2019 Apr; 21(1):106. PubMed ID: 31036055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients.
    Strunz PP; Froehlich M; Gernert M; Schwaneck EC; Fleischer A; Pecher AC; Tony HP; Henes JC; Schmalzing M
    Front Immunol; 2021; 12():723349. PubMed ID: 34539659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients.
    Arruda LCM; Malmegrim KCR; Lima-Júnior JR; Clave E; Dias JBE; Moraes DA; Douay C; Fournier I; Moins-Teisserenc H; Alberdi AJ; Covas DT; Simões BP; Lansiaux P; Toubert A; Oliveira MC
    Blood Adv; 2018 Jan; 2(2):126-141. PubMed ID: 29365321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation.
    Pugnet G; Petermann A; Collot S; Otal P; Lansiaux P; Ait Abdallah N; Lorillon G; Resche-Rigon M; Borel C; Marjanovic Z; Farge D;
    Rheumatology (Oxford); 2023 Feb; 62(SI):SI32-SI42. PubMed ID: 35686921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis.
    Favoino E; Favia IE; Vettori S; Vicenti C; Prete M; Valentini G; Perosa F
    Clin Exp Immunol; 2015 Jul; 181(1):100-9. PubMed ID: 25847615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation.
    Servaas NH; Spierings J; Pandit A; van Laar JM
    Clin Exp Immunol; 2020 Jul; 201(1):34-39. PubMed ID: 31990046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease.
    Bagnato G; Versace AG; La Rosa D; De Gaetano A; Imbalzano E; Chiappalone M; Ioppolo C; Roberts WN; Bitto A; Irrera N; Allegra A; Pioggia G; Gangemi S
    Cells; 2022 Mar; 11(5):. PubMed ID: 35269465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation.
    Gernert M; Tony HP; Schwaneck EC; Fröhlich M; Schmalzing M
    Arthritis Res Ther; 2020 Aug; 22(1):183. PubMed ID: 32771029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Effectiveness of secukinumab in systemic sclerosis with early skin progress after autologous hematopoietic stem cell transplantation and end-stage kidney disease.
    Strunz PP; Labinsky H; Nagler LK; Portegys J; Froehlich M; Gernert M; Schmalzing M
    Front Immunol; 2023; 14():1294496. PubMed ID: 38045701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
    Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis.
    Del Papa N; Onida F; Zaccara E; Saporiti G; Maglione W; Tagliaferri E; Andracco R; Vincenti D; Montemurro T; Mircoli L; Vitali C; Cortelezzi A
    Bone Marrow Transplant; 2017 Jan; 52(1):53-58. PubMed ID: 27548467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.